Physician profile
Baker A Mitchell
NPI 1932113735
$855.14
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $311 · 2021: $29.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $283.55 | 2019-2021 | |
| Abbott Laboratories | $241.44 | 2019-2021 | |
| Horizon Therapeutics Plc | $161.05 | 2019-2020 | |
| Boston Scientific Corporation | $38.38 | 2019 | |
| Shionogi INC | $38.34 | 2019 | |
| Lilly USA, LLC | $37.60 | 2019-2020 | |
| Medtronic USA, INC. | $19.15 | 2019 | |
| Daiichi Sankyo INC. | $12.41 | 2019 | |
| Biodelivery Sciences International, INC. | $12.26 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baker Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.